Skip to main content
PolyPeptide Group AG logo

PolyPeptide Group AG — Investor Relations & Filings

Ticker · PPGN ISIN · CH1110760852 LEI · 5067007JCKTPOX4G9758 SW Manufacturing
Open in API
Filings indexed 111 across all filing types
Latest filing 2022-12-02 Earnings Release
Country CH Switzerland
Listing SW PPGN

About PolyPeptide Group AG

https://www.polypeptide.com/

PolyPeptide Group AG is a Contract Development & Manufacturing Organization (CDMO) specializing in peptide- and oligonucleotide-based active pharmaceutical ingredients (APIs). The company serves the pharmaceutical and biotech sectors by providing a comprehensive range of services that cover all stages of product development, from pre-clinical to commercial manufacturing. Its offerings include both proprietary (custom) and generic GMP-grade peptides. PolyPeptide focuses on innovation in peptide synthesis and manufacturing processes to support the development of therapies for patients.

Recent filings

Filing Released Lang Actions
PolyPeptide provides market update
Earnings Release Classification · 98% confidence The document is explicitly labeled as an 'Ad-hoc' announcement and a 'Media Release – ad hoc announcement pursuant to Art. 53 LR'. It provides a 'market update' which includes lowering the financial guidance for 2022 (revenue and adjusted EBITDA margin) and announcing a change in senior management (appointment of Global Director Operations). This content—a sudden, material update on financial performance and key personnel changes—is characteristic of an immediate disclosure required outside of regular periodic filings. Since it is not a full Annual Report (10-K), a comprehensive Interim Report (IR), or a formal Earnings Release (ER) which typically only contains finalized results, it best fits the category for general regulatory announcements that convey material, non-scheduled information. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for an ad-hoc disclosure that doesn't fit a more specific category like DIV, CAP, or ER, although it contains elements of an ER (lowered guidance) and MANG (management change). However, since it is an immediate, unscheduled disclosure of material non-public information (a profit warning/guidance revision), it functions as a general regulatory disclosure. If 'Ad-hoc' or 'Profit Warning' were options, they would be preferred. Lacking those, RNS serves as the best fit for a general regulatory disclosure announcement. FY 2022
2022-12-02 English
PolyPeptide provides market update
Earnings Release Classification · 99% confidence The document is explicitly titled 'Ad hoc announcement pursuant to Art. 53 LR' and 'Media Release – ad hoc announcement pursuant to Art. 53 LR'. It provides a 'market update' which includes a profit warning (lowered guidance for 2022 revenue and EBITDA margin) and an announcement of a key management change (appointment of Global Director Operations). This type of immediate, material, non-scheduled disclosure, especially one containing a profit warning, is typically classified as an Earnings Release (ER) if it focuses on financial results/guidance, or a Regulatory Filing (RNS) if it's a general ad-hoc disclosure. Since it contains specific financial guidance revisions (a profit warning) and management changes, it functions as an immediate release of material non-public information. Given the options, 'ER' (Earnings Release) is the closest fit for a document primarily focused on revising financial guidance, even though it's an unscheduled update rather than a periodic report. However, because it is an 'Ad hoc announcement' and not a formal quarterly/annual report, and it covers both financial guidance revision and personnel changes, it fits the description of a general regulatory announcement that doesn't fit perfectly into the periodic reporting categories (10-K, IR, ER). The presence of management change alongside the profit warning makes it a broad material disclosure. In many contexts, unscheduled material updates like this are categorized as 'RNS' (Regulatory Filings) when they are not explicitly a transcript (CT) or a formal presentation (IP). Since it is a formal 'Ad hoc announcement' required by listing rules (Art. 53 LR) and contains material updates, RNS is the most appropriate general regulatory fallback, although ER is tempting due to the profit warning. Given the structure and the explicit mention of 'Ad hoc announcement' and the inclusion of personnel changes, RNS is the safer, broader classification for this type of immediate market disclosure not covered by other specific codes like DEF 14A or DIV. FY 2022
2022-12-02 English
PolyPeptide orientiert über den Geschäftsverlauf
Earnings Release Classification · 100% confidence The document is explicitly titled "Ad hoc-Mitteilung gemäss Art. 53 KR" (Ad hoc announcement according to Art. 53 KR) and is a "Medienmitteilung" (Press Release). It provides an update on the business performance, including operational issues, a reduction in the 2022 financial guidance (a profit warning), and an announcement of a management change. This type of unscheduled, material information release, especially one containing a profit warning, is typically classified as an Earnings Release (ER) if it focuses on results/guidance, or a Regulatory Filing (RNS) if it's a general regulatory disclosure. Since it contains specific financial guidance reduction (a key element of an earnings update) but is framed as an immediate, unscheduled announcement (Ad hoc), it aligns best with the 'Earnings Release' (ER) category, which covers initial announcements of periodical financial results/updates, even if unscheduled. It is not a full Annual Report (10-K) or a comprehensive Interim Report (IR). The document also announces a management change, which could suggest MANG, but the primary driver is the financial guidance revision/profit warning. Given the context of financial performance updates and guidance revision, ER is the most appropriate fit among the specific financial codes. It is not a short announcement pointing to another document, so RPA/RNS is less likely than ER. FY 2022
2022-12-02 German
PolyPeptide with encouraging progress within custom projects pipeline however with lower profitability in the first half of 2022
Earnings Release Classification · 100% confidence The document is explicitly titled as an 'Ad-hoc' announcement released on '19 August 2022' and contains 'detailed results for the first half of 2022'. It presents key financial figures (Revenue, Adjusted EBITDA, Result for the period) for H1 2022 compared to H1 2021, along with updated guidance for the full year 2022. This structure—a summary of period results released outside of the main annual or quarterly filing cycle, often via an ad-hoc mechanism—is characteristic of an Earnings Release (ER). Although it mentions the 'Half-Year Report 2022' will be available, the document itself is the initial announcement summarizing those results, not the comprehensive report (which would be classified as IR). The presence of key financial highlights and guidance updates strongly points to ER. H1 2022
2022-08-19 English
PolyPeptide with encouraging progress within custom projects pipeline – however with lower profitability in the first half of 2022
Earnings Release Classification · 100% confidence The document is titled 'Ad hoc announcement pursuant to Art. 53 LR' and explicitly states it is a 'Media Release – ad hoc announcement' detailing the 'detailed results for the first half of 2022'. It provides key financial highlights (Revenue, Adjusted EBITDA, Net result) and updates guidance for 2022. This format, focusing on key figures for a shorter period (H1 2022) and being presented as an immediate market announcement, strongly indicates an Earnings Release (ER). Although it mentions the 'Half-Year Report 2022' will be available, the document itself is the initial announcement of those results, fitting the ER definition better than the comprehensive Interim Report (IR) or the announcement of the report (RPA). H1 2022
2022-08-19 English
PolyPeptide mit vielversprechenden Fortschritten bei den Kundenprojekten – jedoch mit tieferer Profitabilität im ersten Halbjahr 2022
Earnings Release Classification · 100% confidence The document is titled 'Ad hoc-Mitteilung gemäss Art. 53 KR' and explicitly states it announces the 'detaillierten Ergebnisse für das erste Halbjahr 2022' (detailed results for the first half of 2022). It contains key financial metrics (Umsatz, EBITDA, Periodenergebnis) for H1 2022 compared to H1 2021, along with updated guidance. This structure—a comprehensive financial report for a period shorter than a year (H1)—fits the definition of an Interim / Quarterly Report (IR). Although it is presented as an 'Ad hoc-Mitteilung' (which might suggest RPA or RNS), the content is the full set of financial results and analysis for the half-year, not just an announcement that a report is available. Therefore, it is classified as an Interim Report (IR). H1 2022
2022-08-19 German

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.